Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leftover tumor after breast cancer treatment: a hidden risk revealed

NCT ID NCT07714382

Completed Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks back at medical records of women with triple-negative breast cancer who had chemotherapy and radiation before surgery. It focuses on those who still had cancer cells left after treatment (residual disease) and tracks how long they lived without the cancer coming back. The goal is to understand which factors are linked to worse outcomes, so doctors can better identify who needs more aggressive follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help identify which patients with residual TNBC are at highest risk, guiding more personalized follow-up and treatment decisions.
What could go wrong
As a retrospective study, it can show associations but not prove cause and effect. Results may be limited by the quality and completeness of medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

  • Sohag university

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.